doi: 10.1038/sj.clpt.6100017.
Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
Affiliations
- PMID: 17186007
- DOI: 10.1038/sj.clpt.6100017
Item in Clipboard
Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
Clin Pharmacol Ther.
2007 Jan.
Abstract
A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and subsequent application of biomarkers in drug development. One key activity is biomarker qualification, a graded, "fit-for-purpose" evidentiary process linking a biomarker with biology and clinical end points. A biomarker consortium model will distribute cost and risk, and drive efficient execution of research and ultimately regulatory acceptance of biomarkers for specific indications.
Similar articles
-
Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.Pharmacotherapy. 2005 Dec;25(12 Pt 2):109S-123S. doi: 10.1592/phco.2005.25.12part2.109S. Pharmacotherapy. 2005. PMID: 16305280 Review.
-
Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):127-37. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10698472 Review.
-
Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1419-27. J Clin Pharmacol. 2000. PMID: 11185662 Review.
-
Strategic approach to fit-for-purpose biomarkers in drug development.Annu Rev Pharmacol Toxicol. 2008;48:631-51. doi: 10.1146/annurev.pharmtox.48.113006.094611. Annu Rev Pharmacol Toxicol. 2008. PMID: 17937595 Review.
-
Statistical evaluation of biomarkers as surrogate endpoints: a literature review.Stat Med. 2006 Jan 30;25(2):183-203. doi: 10.1002/sim.2319. Stat Med. 2006. PMID: 16252272 Review.
Cited by
-
Development and use of integral assays in clinical trials.Clin Cancer Res. 2012 Mar 15;18(6):1540-6. doi: 10.1158/1078-0432.CCR-11-2202. Clin Cancer Res. 2012. PMID: 22422406 Free PMC article.
-
Neuroimaging-based pain biomarkers: definitions, clinical and research applications, and evaluation frameworks to achieve personalized pain medicine.Pain Rep. 2019 Aug 7;4(4):e762. doi: 10.1097/PR9.0000000000000762. eCollection 2019 Jul-Aug. Pain Rep. 2019. PMID: 31579854 Free PMC article. Review.
-
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective.J Bone Miner Res. 2008 Aug;23(8):1155-67. doi: 10.1359/jbmr.080301. J Bone Miner Res. 2008. PMID: 18318643 Free PMC article.
-
Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms.Curr Neuropharmacol. 2018;16(4):484-504. doi: 10.2174/1570159X15666170828165711. Curr Neuropharmacol. 2018. PMID: 28847295 Free PMC article. Review.
-
A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer.FEBS J. 2009 Apr;276(8):2157-64. doi: 10.1111/j.1742-4658.2009.06934.x. Epub 2009 Feb 25. FEBS J. 2009. PMID: 19250312 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
